New York Medical Marijuana Bill on Horizon, Lawmaker

New Post Public Reply Private Reply Replies (1) Message Board
geo

New York Medical Marijuana Bill on Horizon, Lawmaker Says Support ‘Growing by the Day’

savino3

A Democratic lawmaker plans to introduce a bill soon calling for the legalization of medical cannabis in New York, reigniting the MMJ debate in a crucial market for the marijuana movement.

New York State Sen. Diane Savino told Medical Marijuana Business Daily that the measure is being drafted and will be ready for introduction in the next few days. She is extremely optimistic about its chances, saying that support is “growing every day” in the Senate, where previous  marijuana-related measures have died .

“I’m hoping the bill will be ready by the end of week, and if not then the beginning of next week,” Savino said, adding that identical measures will be introduced in the state Assembly and Senate simultaneously.

The measure would set up a strict regulatory framework covering medical marijuana production and sales, using MMJ programs in states like Colorado and Connecticut as models. The industry would be subject to heavy oversight and numerous rules covering everything from security to permits and registration. The bill also would require comprehensive inventory tracking, from the time the seed is planted to the time cannabis is harvested, packaged and sold to patients.

“What we want to do is adopt the best practices and reject the worst to put forward a bill that will stand up to public scrutiny,” Savino said. “We also want to do everything possible to avoid aggressive intervention by the federal government, and the best way to accomplish that is through a tightly controlled statute that doesn’t allow for a lot of wiggle room.”

Under the bill, dispensaries could be either for-profit or nonprofit. The list of qualifying medical conditions would be very specific, including  diseases and aliments such as HIV/AIDS, cancer, diabetes and multiple sclerosis. The idea is to avoid vague conditions like “chronic pain” that have inflated patient numbers and led to criticism in some other states.

Patients would have to buy medical cannabis from approved dispensaries and would not be able to grow their own.

It’s an important bill for the medical cannabis industry. New York is seen as an important state for medical marijuana because of its size – more than 19 million residents – and influence on the national stage. The market would be somewhat limited, with perhaps just tens of thousands of patients qualifying for MMJ cards initially because of the short list of qualifying conditions. But legalization in NY would still create hundreds of new business opportunities and give the industry even more clout, which could help convince other states weighing medical cannabis measures to follow suit.

The bill could sail through the Assembly – which has passed similar measures before – and Savino said she believes there’s enough support in the Senate. If the proposal clears those hurdles, it would wind up on the desk of New York Gov. Andrew Cuomo.

Getting his stamp of approval could be a challenge. Cuomo has said he is against the legalization of medical cannabis. But he has softened his position recently and agreed to explore the issue further. The governor is also  pushing to decriminalize the possession of small amounts of marijuana.

Savino said she is confident that supporters can convince the governor to give the bill the green light if it passes the Assembly and Senate, though she admits it will take some work.

“Some people in his administration seem amendable to this, but we’d need to sit down and talk through this with the governor,” she said.

Lisa Reid – a senior associate at Patricia Lynch Associates, which is lobbying lawmakers to adopt MMJ laws on behalf of a Colorado company – said the bill stands a much better chance of passing than previous measures in part because it calls for extremely tight regulations.

“Our Republicans friends here in the Senate have found themselves far more comfortable with this model” than others, Reid said. “The fact is that Colorado has the best model, and that model is best for New York.”

She said the biggest fear in New York is that a huge black market will develop. “When you have a tightly regulated system…government oversight, a bar code issued from the time to plant is viable to a bud getting into patients’ hands, you essentially eliminate the black market to the best of your ability,” Reid said. “And when you have a for-profit model, everything is transparent, nothing is underground, and you have the least amount of intervention by the federal government.”

The current legislative session ends June 20, so it’s possible New York will become the 19th state to legalize medical marijuana by summer.

In anticipation of legalization, some professionals are already exploring ways to get involved. Based on the high level of interest in the market, Medical Marijuana Business Daily will hold a seminar in New York City for entrepreneurs and investors who want to learn more about the cannabis industry and opportunities in the region, including Connecticut and New Jersey (both of which have already legalized MMJ). You can find  more information about the seminar or purchase tickets here .

Related Stories

Rapid Fire Marketing, Inc. (RFMK) Stock Research Links

RFMK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 446

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 333

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 38

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 90

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 104

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

SOCi's AI Marketing: Leading G2's Summer 2026 Rankings

Updated Category News Views 12

AI's Rising Star in Enterprise Marketing Here's a tidbit worth chewing over your morning coffee: SOCi Inc., a name that's been buzzing in the enterprise circles, has nailed top spots in G2's Summer 2026 Report. We're talking about leading the charge in AI marketing and localized visibility, territories tough to crack unless you've got serious chops. In a world where...

Continue Reading
AI and the Future of Staffing: A Market Growth Story

Updated Category News Views 344

AI and the Future of Staffing: A Growth Story The staffing services market is on the verge of a major transformation, thanks in large part to advancements in Artificial Intelligence (AI). This evolution is projected to add an astounding USD 236.6 billion to the global staffing services market between 2024 and 2028. During this time, the market is expected to experience a...

Continue Reading
Optical Innovations Unite: OCC and Lightera's New Partnership

Updated Category News Views 317

Strategic Collaboration Between OCC and Lightera Optical Cable Corporation (NASDAQ: OCC) and Lightera, LLC are entering a significant partnership aimed at enhancing their product offerings primarily in the data center and enterprise sectors. This collaboration builds upon their long-term relationship, combining their strengths to create innovative optical connectivity...

Continue Reading
INFINOX Welcomes Artem Gonov as New Chief Technology Officer

Updated Category News Views 148

INFINOX Appoints Artem Gonov as Chief Technology Officer INFINOX, a globally recognized brokerage, has recently appointed Artem Gonov as its new Chief Technology Officer (CTO). This strategic move underlines the company's commitment to enhancing its technology landscape and providing exceptional platforms for its clients. Artem Gonov's Background and Expertise Mr. Gonov...

Continue Reading
George Medicines’ GMRx2 Sets New Standard for Hypertension Care

Updated Category News Views 126

George Medicines Introduces GMRx2 for Hypertension Management Recent findings published in The Lancet highlighted the promising results of a Phase III trial for GMRx2, a novel triple combination pill aimed at managing hypertension. Developed by George Medicines, this medication is making waves in the field of cardiovascular care as it demonstrates significant advancements...

Continue Reading